Lumateperone

Breastfeeding
  • TRADE NAME: Caplyta (Intra-Cellular Therapies)
  • INDICATIONS: Treatment of schizophrenia in adults.
  • CLASS: Antipsychotic
  • HALF-LIFE: ~18 hours

FDA APPROVAL DATE: 12/20/2019

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Amprenavir, Aprepitant, Armodafinil, Carbamazepine, Ciprofloxacin, Clarithromycin, Cyclosporine, CYP3A4 inducers, Diltiazem, Efavirenz, Erythromycin, Etravirine, Fluconazole, Fluvoxamine, Grapefruit Juice, Itraconazole, Modafinil, moderate or strong CYP3A4 inhibitors, Nafcillin, Nefazodone, Nelfinavir, Phenytoin, Pioglitazone, Prednisone, Probenecid, Rifampin, Ritonavir, St John's Wort, UGT inhibitors, Valproic Acid, Verapamil, Voriconazole


May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. Breastfeeding is not recommended.
NOTE

Avoid use in patients with moderate or severe hepatic impairment (Child-Pugh B or C).

BLACK BOX WARNING

INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED
PSYCHOSIS

ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS TREATED WITH ANTIPSYCHOTIC DRUGS ARE AT AN INCREASED RISK OF DEATH. LUMATEPERONE IS NOT APPROVED FOR THE TREATMENT OF PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS.

 


See full prescribing information for complete boxed warning

Our database has 12 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.


Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top